CORMEDIX INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
CORMEDIX INC. (CRMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $7.16 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2023-03-30
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2021-03-31 was $4.71, a 47.72% decline year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2020-03-31 was $9.01, a 39.69% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2019-03-31 was $6.45, a 357.45% increase year-over-year.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2018-03-31 was $1.41.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $7.16, a 7.25% decline from fiscal 2021.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2021 was $7.72, a 9.28% decline from fiscal 2020.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $8.51, a 10.09% increase from fiscal 2019.
- CORMEDIX INC. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2019 was $7.73, a 472.59% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $7.16 10-K · filed 2023-03-30 | ||||
| 2021-12-31 | $7.72 10-K · filed 2022-03-29 | ||||
| 2021-06-30 | $5.50 10-Q · filed 2021-08-12 | ||||
| 2021-03-31 | $4.71 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | $8.51 10-K · filed 2021-03-30 | ||||
| 2020-09-30 | $9.01 10-Q · filed 2020-11-05 | ||||
| 2020-06-30 | $9.01 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $9.01 10-Q · filed 2020-05-11 | ||||
| 2019-12-31 | $7.73 10-K · filed 2020-03-16 | ||||
| 2019-09-30 | $6.45 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $6.45 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $6.45 10-Q · filed 2019-05-13 | ||||
| 2018-12-31 | $1.35 10-K · filed 2019-05-29 | ||||
| 2018-06-30 | $1.41 10-Q · filed 2018-08-14 | ||||
| 2018-03-31 | $1.41 10-Q · filed 2018-05-15 | ||||
| 2017-12-31 | $2.97 10-K · filed 2018-03-19 | ||||
| 2017-09-30 | $1.85 10-Q · filed 2017-11-09 | ||||
| 2017-06-30 | $2.24 10-Q · filed 2017-08-09 | ||||
| 2017-03-31 | $0.00 10-Q · filed 2017-05-10 | ||||
| 2016-12-31 | $2.73 10-K · filed 2017-03-16 | ||||
| 2015-12-31 | $2.97 10-K · filed 2016-03-15 | ||||
| 2014-12-31 | $2.65 10-K · filed 2016-03-15 | ||||
| 2014-03-31 | $3.16 10-Q · filed 2014-05-15 | ||||
| 2013-12-31 | $1.61 10-K · filed 2015-03-12 | ||||
| 2013-09-30 | $1.61 10-Q/A · filed 2014-03-04 | ||||
| 2012-12-31 | $3.13 10-K · filed 2014-03-31 | $1.72 10-K/A · filed 2014-03-04 | |||
| 2012-09-30 | $3.13 10-Q/A · filed 2014-03-04 | ||||
| 2011-12-31 | $2.79 10-K/A · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |